Table 1 Patient and lesion characteristics
Characteristic | |
Number of patients total | 23 |
Age median (range) | 59 (46–82) |
Gender, number of patients (%) | |
Male | 13 (56.5%) |
Female | 10 (43.5%) |
Histology | |
Clear cell RCC | 23 (100%) |
Treatment, number of patients (%) | |
Sunitinib | 14 (60.9%) |
Pazopanib | 5 (21.7%) |
Cediranib | 2 (8.7%) |
Regorafenib | 2 (8.7%) |
Lesions, number of lesions (%) | |
Lung/pleura | 18 (32.1%) |
Lymph node | 11 (19.6%) |
Liver | 11 (19.6%) |
Adrenal gland | 8 (14.3%) |
Pancreas | 5 (8.9%) |
Other site | 3 (5.4%) |
Baseline characteristics of the lesions, median (range) | |
Longest diameter of lesion | 28.5 (10 to 111.4) mm |
Volume of lesion | 7.95 (0.21 to 317.2) ml |
Mean enhancement of lesion | 93 (35 to 242) HU |
Normalised mean enhancement (nE) of lesion | 0.372 (0.136 to 0.650) nHU |
Lesion response, baseline to first on-treatment scan median (range) | |
Percentage change in diameter | −8.2 (−73.2 to +73.8)% |
Percentage change in nE | −41.3 (−87.3 to +57.9)% |
